Trial Profile
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary) ; Paclitaxel
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 31 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2010 Planned end date changed from 1 Jul 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 13 Dec 2008 New trial record.